90 research outputs found

    Devices and methods of operation thereof for providing stable flow for centrifugal compressors

    Get PDF
    Centrifugal compressor flow stabilizing devices and methods of operation thereof are disclosed that act upon the flow field discharging from the impeller of a centrifugal compressor and modify the flow field ahead of the diffuser vanes such that flow conditions contributing to rotating stall and surge are reduced or even eliminated. In some embodiments, shaped rods and methods of operation thereof are disclosed, whereas in other embodiments reverse-tangent air injection devices and methods are disclosed

    Computational Study of the CC3 Impeller and Vaneless Diffuser Experiment

    Get PDF
    Centrifugal compressors are compatible with the low exit corrected flows found in the high pressure compressor of turboshaft engines and may play an increasing role in turbofan engines as engine overall pressure ratios increase. Centrifugal compressor stages are difficult to model accurately with RANS CFD solvers. A computational study of the CC3 centrifugal impeller in its vaneless diffuser configuration was undertaken as part of an effort to understand potential causes of RANS CFD mis-prediction in these types of geometries. Three steady, periodic cases of the impeller and diffuser were modeled using the TURBO Parallel Version 4 code: (1) a k- turbulence model computation on a 6.8 million point grid using wall functions, (2) a k- turbulence model computation on a 14 million point grid integrating to the wall, and (3) a k- turbulence model computation on the 14 million point grid integrating to the wall. It was found that all three cases compared favorably to data from inlet to impeller trailing edge, but the k- and k- computations had disparate results beyond the trailing edge and into the vaneless diffuser. A large region of reversed flow was observed in the k- computations which extended from 70 to 100 percent span at the exit rating plane, whereas the k- computation had reversed flow from 95 to 100 percent span. Compared to experimental data at near-peak-efficiency, the reversed flow region in the k- case resulted in an underprediction in adiabatic efficiency of 8.3 points, whereas the k- case was 1.2 points lower in efficiency

    Laser Anemometer Measurements of the Flow Field in a 4:1 Pressure Ratio Centrifugal Impeller

    Get PDF
    A laser-doppler anemometer was used to obtain flow-field velocity measurements in a 4:1 pressure ratio, 4.54 kg/s (10 lbm/s), centrifugal impeller, with splitter blades and backsweep, which was configured with a vaneless diffuser. Measured through-flow velocities are reported for ten quasi-orthogonal survey planes at locations ranging from 1% to 99% of main blade chord. Measured through-flow velocities are compared to those predicted by a 3-D viscous steady flow analysis (Dawes) code. The measurements show the development and progression through the impeller and vaneless diffuser of a through-flow velocity deficit which results from the tip clearance flow and accumulation of low momentum fluid centrifuged from the blade and hub surfaces. Flow traces from the CFD analysis show the origin of this deficit which begins to grow in the inlet region of the impeller where it is first detected near the suction surface side of the passage. It then moves toward the pressure side of the channel, due to the movement of tip clearance flow across the impeller passage, where it is cut by the splitter blade leading edge. As blade loading increases toward the rear of the channel the deficit region is driven back toward the suction surface by the cross-passage pressure gradient. There is no evidence of a large wake region that might result from flow separation and the impeller efficiency is relatively high. The flow field in this impeller is quite similar to that documented previously by NASA Lewis in a large low-speed backswept impeller

    Variable-Speed Power-Turbine Research at Glenn Research Center

    Get PDF
    The main rotors of the NASA Large Civil Tilt-Rotor (LCTR) notional vehicle operate over a wide speed-range, from 100 percent at takeoff to 54 percent at cruise. The variable-speed power turbine (VSPT) offers one approach by which to effect this speed variation. VSPT aerodynamics challenges include high work factors at cruise, wide (40 to 60 ) incidence-angle variations in blade and vane rows over the speed range, and operation at low Reynolds numbers. Rotordynamics challenges include potential responsiveness to shaft modes within the 50 percent VSPT speed-range. A research effort underway at NASA Glenn Research Center, intended to address these key aerodynamic and rotordynamic challenges, is described. Conceptual design and 3-D multistage RANS and URANS analyses, conducted internally and under contract, provide expected VSPT sizing, stage-count, performance and operability information, and maps for system studies. Initial steps toward experimental testing of incidence-tolerant blading in a transonic linear cascade are described, and progress toward development/improvement of a simulation capability for multistage turbines with low Reynolds number transitional flow is summarized. Preliminary rotordynamics analyses indicate that viable concept engines with 50 percent VSPT shaft-speed range. Assessments of potential paths toward VSPT component-level testing are summarized

    Angiotensin type 1 receptor antagonist losartan, reduces MPTP-induced degeneration of dopaminergic neurons in substantia nigra

    Get PDF
    BACKGROUND: Recent attention has focused on understanding the role of the brain-renin-angiotensin-system (RAS) in stroke and neurodegenerative diseases. Direct evidence of a role for the brain-RAS in Parkinson's disease (PD) comes from studies demonstrating the neuroprotective effect of RAS inhibitors in several neurotoxin based PD models. In this study, we show that an antagonist of the angiotensin II (Ang II) type 1 (AT(1)) receptor, losartan, protects dopaminergic (DA) neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) toxicity both in primary ventral mesencephalic (VM) cultures as well as in the substantia nigra pars compacta (SNpc) of C57BL/6 mice (Fig. 1). RESULTS: In the presence of exogenous Ang II, losartan reduced MPP(+ )(5 μM) induced DA neuronal loss by 72% in vitro. Mice challenged with MPTP showed a 62% reduction in the number of DA neurons in the SNpc and a 71% decrease in tyrosine hydroxylase (TH) immunostaining of the striatum, whereas daily treatment with losartan lessened MPTP-induced loss of DA neurons to 25% and reduced the decrease in striatal TH(+ )immunostaining to 34% of control. CONCLUSION: Our study demonstrates that the brain-RAS plays an important neuroprotective role in the MPTP model of PD and points to AT(1 )receptor as a potential novel target for neuroprotection

    Combined intervention with pioglitazone and n-3 fatty acids in metformin-treated type 2 diabetic patients: improvement of lipid metabolism

    No full text
    Background: The marine n-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) exert numerous beneficial effects on health, but their potency to improve treatment of type 2 diabetic (T2D) patients remains poorly characterized. We aimed to evaluate the effect of a combination intervention using EPA?+?DHA and the insulin-sensitizing drug pioglitazone in overweight/obese T2D patients already treated with metformin.Methods: In a parallel-group, four-arm, randomized trial, 69 patients (66 % men) were assigned to 24-week-intervention using: (i) corn oil (5 g/day; Placebo), (ii) pioglitazone (15 mg/day; Pio), (iii) EPA?+?DHA concentrate (5 g/day, containing ~2.8 g EPA?+?DHA; Omega-3), or (iv) pioglitazone and EPA?+?DHA concentrate (Pio&amp; Omega-3). Data from 60 patients were used for the final evaluation. At baseline and after intervention, various metabolic markers, adiponectin and cytokines were evaluated in serum using standard procedures, EPA?+?DHA content in serum phospholipids was evaluated using shotgun lipidomics and mass spectrometry, and hyperinsulinemic-euglycemic clamp and meal test were also performed. Indirect calorimetry was conducted after the intervention. Primary endpoints were changes from baseline in insulin sensitivity evaluated using hyperinsulinemic-euglycemic clamp and in serum triacylglycerol concentrations in fasting state. Secondary endpoints included changes in fasting glycemia and glycated hemoglobin (HbA1c), changes in postprandial glucose, free fatty acid and triacylglycerol concentrations, metabolic flexibility assessed by indirect calorimetry, and inflammatory markers.Results: Omega-3 and Pio&amp; Omega-3 increased EPA?+?DHA content in serum phospholipids. Pio and Pio&amp; Omega-3 increased body weight and adiponectin levels. Both fasting glycemia and HbA1c were increased by Omega-3, but were unchanged by Pio&amp; Omega-3. Insulin sensitivity was not affected by Omega-3, while it was improved by Pio&amp; Omega-3. Fasting triacylglycerol concentrations and inflammatory markers were not significantly affected by any of the interventions. Lipid metabolism in the meal test and metabolic flexibility were additively improved by Pio&amp; Omega-3.Conclusion: Besides preventing a modest negative effect of n-3 fatty acids on glycemic control, the combination of pioglitazone and EPA?+?DHA can be used to improve lipid metabolism in T2D patients on stable metformin therapy.Trial registration: EudraCT number 2009-011106-42.<br/

    Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy

    Get PDF
    Accumulation of amyloid-beta (Aβ) into senile plaques in Alzheimer’s disease (AD) is a hallmark neuropathological feature of the disorder, which likely contributes to alterations in neuronal structure and function. Recent work has revealed changes in neurite architecture associated with plaques and functional changes in cortical signaling in amyloid precursor protein (APP) expressing mouse models of AD. Here we developed a method using gene transfer techniques to introduce GFP into neurons allowing the investigation of neuronal processes in the vicinity of plaques. Multiphoton imaging of GFP-labeled neurons in living Tg2576 APP mice revealed disrupted neurite trajectories and reductions in dendritic spine density compared to age-matched control mice. A profound deficit in spine density (∼50%) extends approximately 20 μm from plaque edges. Importantly, a robust decrement (∼25%) also occurs on dendrites not associated with plaques, suggesting widespread loss of postsynaptic apparatus. Plaques and dendrites remained stable over the course of weeks of imaging. Post-mortem analysis of axonal immunostaining and co-localization of synaptophysin and postsynaptic density 95 (PSD-95) protein staining around plaques indicate a parallel loss of pre- and postsynaptic partners. These results show considerable changes in dendrites and dendritic spines in APP transgenic mice, demonstrating a dramatic synaptotoxic effect of dense core plaques. Decreased spine density will likely contribute to altered neural system function and behavioral impairments observed in Tg2576 mice

    In Vivo Detection of Amyloid-β Deposits Using Heavy Chain Antibody Fragments in a Transgenic Mouse Model for Alzheimer's Disease

    Get PDF
    This study investigated the in vivo properties of two heavy chain antibody fragments (VHH), ni3A and pa2H, to differentially detect vascular or parenchymal amyloid-β deposits characteristic for Alzheimer's disease and cerebral amyloid angiopathy. Blood clearance and biodistribution including brain uptake were assessed by bolus injection of radiolabeled VHH in APP/PS1 mice or wildtype littermates. In addition, in vivo specificity for Aβ was examined in more detail with fluorescently labeled VHH by circumventing the blood-brain barrier via direct application or intracarotid co-injection with mannitol. All VHH showed rapid renal clearance (10–20 min). Twenty-four hours post-injection 99mTc-pa2H resulted in a small yet significant higher cerebral uptake in the APP/PS1 animals. No difference in brain uptake were observed for 99mTc-ni3A or DTPA(111In)-pa2H, which lacked additional peptide tags to investigate further clinical applicability. In vivo specificity for Aβ was confirmed for both fluorescently labeled VHH, where pa2H remained readily detectable for 24 hours or more after injection. Furthermore, both VHH showed affinity for parenchymal and vascular deposits, this in contrast to human tissue, where ni3A specifically targeted only vascular Aβ. Despite a brain uptake that is as yet too low for in vivo imaging, this study provides evidence that VHH detect Aβ deposits in vivo, with high selectivity and favorable in vivo characteristics, making them promising tools for further development as diagnostic agents for the distinctive detection of different Aβ deposits

    Non-Hodgkin lymphoma response evaluation with MRI texture classification

    Get PDF
    <p>Abstract</p> <p>Background</p> <p>To show magnetic resonance imaging (MRI) texture appearance change in non-Hodgkin lymphoma (NHL) during treatment with response controlled by quantitative volume analysis.</p> <p>Methods</p> <p>A total of 19 patients having NHL with an evaluable lymphoma lesion were scanned at three imaging timepoints with 1.5T device during clinical treatment evaluation. Texture characteristics of images were analyzed and classified with MaZda application and statistical tests.</p> <p>Results</p> <p>NHL tissue MRI texture imaged before treatment and under chemotherapy was classified within several subgroups, showing best discrimination with 96% correct classification in non-linear discriminant analysis of T2-weighted images.</p> <p>Texture parameters of MRI data were successfully tested with statistical tests to assess the impact of the separability of the parameters in evaluating chemotherapy response in lymphoma tissue.</p> <p>Conclusion</p> <p>Texture characteristics of MRI data were classified successfully; this proved texture analysis to be potential quantitative means of representing lymphoma tissue changes during chemotherapy response monitoring.</p
    • …
    corecore